Skip to content

Study · Non-randomized trial · n = 51 · 2003

9 results

Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.

Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Nov 2003Cited by 414 (Europe PMC)

PMID14606504 (opens in a new tab)DOI10.1359/jbmr.2003.18.11.1932 (opens in a new tab)PepBankPUB-14606504
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, pooled teriparatide doses increased cancellous bone volume compared with placebo.

    In plain wordsIn women with postmenopausal osteoporosis, teriparatide increased cancellous bone volume more than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous bone volume
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Measurements

    Median bone volume change
    14%
    Teriparatide
    Median bone volume change
    −24%
    Placebo

    Source sentences

    Summary
    By 2D histomorphometric analyses, teriparatide significantly increased cancellous bone volume (median percent change: teriparatide, 14%; placebo, -24%; p = 0.001)
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, teriparatide reduced marrow star volume compared with placebo.

    In plain wordsIn women with postmenopausal osteoporosis, teriparatide reduced marrow star volume compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMarrow star volume
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Measurements

    Percent change in marrow star volume
    −16%
    Teriparatide
    Percent change in marrow star volume
    112%
    Placebo

    Source sentences

    Summary
    and reduced marrow star volume (teriparatide, -16%; placebo, 112%; p = 0.004).
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, teriparatide decreased cancellous structure model index compared with placebo.

    In plain wordsIn women with osteoporosis, teriparatide decreased the cancellous structure model index compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCancellous structure model index
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Measurements

    Percent change in cancellous structure model index
    −12%
    Teriparatide
    Percent change in cancellous structure model index
    7%
    Placebo

    Source sentences

    Summary
    By 3D cancellous and cortical bone structural analyses, teriparatide significantly decreased the cancellous structure model index (teriparatide, -12%; placebo, 7%; p = 0.025)
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, teriparatide increased cancellous connectivity density compared with placebo.

    In plain wordsIn women with osteoporosis, teriparatide increased bone connectivity compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous connectivity density
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Measurements

    Percent change in cancellous connectivity density
    19%
    Teriparatide
    Percent change in cancellous connectivity density
    −14%
    Placebo

    Source sentences

    Summary
    increased cancellous connectivity density (teriparatide, 19%; placebo, - 14%; p = 0.034)
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, teriparatide increased cortical thickness compared with placebo.

    In plain wordsIn women with osteoporosis, teriparatide increased cortical bone thickness compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical thickness
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Measurements

    Percent change in cortical thickness
    22%
    Teriparatide
    Percent change in cortical thickness
    3%
    Placebo

    Source sentences

    Summary
    and increased cortical thickness (teriparatide, 22%; placebo, 3%; p = 0.012).
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  6. 06HumanNon-randomized trialSafety outcome

    In women with postmenopausal osteoporosis, teriparatide was not associated with osteomalacia.

    In plain wordsIn women with postmenopausal osteoporosis, teriparatide was not associated with osteomalacia.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableOsteomalacia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Source sentences

    Summary
    Teriparatide administration was not associated with osteomalacia or woven bone, and there were no significant changes in mineral appositional rate or wall thickness.
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  7. 07HumanNon-randomized trialSafety outcome

    In women with postmenopausal osteoporosis, teriparatide was not associated with woven bone.

    In plain wordsIn women with postmenopausal osteoporosis, teriparatide was not associated with woven bone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableWoven bone
    Study

    n: not reported in source

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Source sentences

    Summary
    Teriparatide administration was not associated with osteomalacia or woven bone, and there were no significant changes in mineral appositional rate or wall thickness.
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  8. 08HumanNon-randomized trialEfficacy outcome

    In teriparatide-treated women with osteoporosis, mineral appositional rate did not change significantly.

    In plain wordsIn women with osteoporosis, mineral appositional rate did not change significantly with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeMineral appositional rate
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Source sentences

    Summary
    Teriparatide administration was not associated with osteomalacia or woven bone, and there were no significant changes in mineral appositional rate or wall thickness.
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…
  9. 09HumanNon-randomized trialEfficacy outcome

    In teriparatide-treated women with osteoporosis, wall thickness did not change significantly.

    In plain wordsIn women with osteoporosis, bone wall thickness did not change significantly with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeWall thickness
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg · Mean 19 monthsAs given in this study (human).

    Source sentences

    Summary
    Teriparatide administration was not associated with osteomalacia or woven bone, and there were no significant changes in mineral appositional rate or wall thickness.
    2 context sentences
    Summary · context
    We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months.
    Summary · context
    Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatme…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.